Today: 9 June 2026
Browse Category

NASDAQ:ADAP 19 August 2025 - 16 October 2025

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune Therapeutics shares surged 42% on October 8, 2025, after nearly doubling intraday on September 19, despite no major news and record trading volumes. The company sold its key T-cell therapy programs, including Tecelra, to US WorldMeds for $55 million upfront to pay off debt and avoid insolvency. Q2 net loss reached $30.3 million, with cash reserves at $26 million by mid-year. Analysts remain bearish, with no major buy ratings.
16 October 2025
··
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune shares jumped 52% on October 8, 2025, amid heavy speculative trading, but remain down about 75% year-over-year and trade near $0.20. The company sold its main T-cell therapy programs to US WorldMeds for $55 million upfront, cleared its debt, and now faces “substantial doubt” about its ability to continue. Analysts rate the stock as high risk, with no major firm recommending a Buy.
9 October 2025
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics shares soared 42% to around $0.20 on Oct. 8, 2025, after weeks of extreme volatility and trading volumes topping 705 million shares. The company sold its four main cell therapy programs, including newly approved Tecelra, for $55 million upfront in July to pay off debt and cut its workforce by 62%. Weiss Ratings issued a rare “Sell (E+)” on Oct. 8. No new products have been announced this month.
8 October 2025
·
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····

Stock Market Today

  • SpaceX IPO 2026: Key Facts and Considerations
    June 8, 2026, 6:15 PM EDT. SpaceX, Elon Musk's private aerospace giant, is eyeing an initial public offering (IPO) in 2026. An IPO is when a company offers its shares to the public for the first time. Investors anticipating the SpaceX IPO should note the company's role in satellite technology and space exploration, sectors poised for growth. Market watchers will monitor valuation, timing, and regulatory factors as SpaceX transitions from private funding to public markets. Understanding these elements is crucial for stakeholders considering exposure to aerospace innovation and potential returns.

Latest articles

UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

9 June 2026
UBS upgraded Cummins to Buy and hiked its price target to $850 from $565, citing surging data-center backup power demand and a stronger North American truck cycle; Cummins shares jumped 3.3% to $672.68 as UBS projected 2028 EPS of $41.25, topping consensus, and flagged double-digit Power business growth and raised long-term targets as key drivers.
UiPath Stock Slips Near $11 as Wall Street Questions the AI Automation Bounce

UiPath Stock Slips Near $11 as Wall Street Questions the AI Automation Bounce

8 June 2026
UiPath shares dipped 0.7% to $11.17 despite a strong quarter and raised outlook, as investors focused on slow annual recurring revenue growth and analyst caution, with Morgan Stanley cutting its price target and BofA maintaining Underperform, citing the need for clearer evidence that AI-driven automation can accelerate durable contract revenue.
IREN Shares Rally After Bitcoin Rebound and $4.4 Billion AI Data Center Move

IREN Shares Rally After Bitcoin Rebound and $4.4 Billion AI Data Center Move

8 June 2026
IREN surged 9% to $59.19 as investors returned to crypto and AI infrastructure stocks after last week’s selloff, driven by a $3.65 billion investment-grade GPU financing to support its Microsoft AI cloud contract and news of a planned 800MW data-center in Australia, but future gains hinge on execution, contract delivery, and bitcoin price stability.
SmartKem Shares Jump 100% on SRx Investment, SMTK in Focus

SmartKem Shares Jump 100% on SRx Investment, SMTK in Focus

8 June 2026
SmartKem shares soared as much as 150% to $1.135 before settling at $0.84 after SRx Health Solutions disclosed a 4.99% stake and purchase of convertible preferred securities, injecting new investor interest as SmartKem faces a Sept. 1 Nasdaq delisting risk for trading below $1 and warns of “substantial doubt” about its ability to continue as a going concern.
Texxon Trading Halted Six Times as NPT Jumps 284% in New York

Texxon Trading Halted Six Times as NPT Jumps 284% in New York

8 June 2026
Texxon shares soared 283.7% to $4.95, briefly topping $12 before closing just below their $5 IPO price, with trading paused six times for volatility and volume over six times shares outstanding; the company warned that similar IPOs had seen sharp, non-fundamental price swings, highlighting ongoing risk for investors.
Go toTop